Juhani Airaksinen

Internal Medicine (Department of Clinical Medicine)

juhair@utu.fi

ORCID identifier: https://orcid.org/orcid.org/0000-0002-0193-568X

Publications

34 of 60

Vajaatoimintapotilaiden äkkikuoleman vaara on pienenemässä (2017)
- Lääkärilehti
Airaksinen Juhani
(Other publication)
Voidaanko sydäninfarktipotilaan lääkehoitomyöntyvyyttä parantaa? (2017)
- Lääkärilehti
Airaksinen Juhani
(Other publication)
Anticoagulation, CHA(2)DS(2)VASc Score, and Thromboembolic Risk of Cardioversion of Acute Atrial Fibrillation (from the FinCV Study) (2016)
- American Journal of Cardiology
Toni Grönberg, Juha E. K. Hartikainen, Ilpo Nuotio, Fausto Biancari, Antti Ylitalo, K. E. Juhani Airaksinen
(A1 Refereed original research article in a scientific journal)
Clinical factors associated with initiation of and persistence with ADP receptor-inhibiting oral antiplatelet treatment after acute coronary syndrome: a nationwide cohort study from Finland (2016)
- BMJ Open
Tuire Prami, Houssem Khanfir, Anna Deleskog, Pål Haswold, Ville Kytö, Eeva Reissell, Juhani Airaksinen
(A1 Refereed original research article in a scientific journal)
Comparison of international normalized ratio audit parameters in patients enrolled in GARFIELD-AF and treated with vitamin K antagonists (2016)
- British Journal of Haematology
Fitzmaurice DA, Accetta G, Haas S, Kayani G, Lucas Luciardi H, Misselwitz F, Pieper K, Ten Cate H, Turpie AG, Kakkar AK; and for the GARFIELD-AF Investigators
(A1 Refereed original research article in a scientific journal)
Dabigatran etexilate and reduction in serum apolipoprotein B (2016)
- Heart
Joseph P, Pare G, Wallentin L, Connolly S, Yusuf S, Wang J, Ezekowitz M, Eikelboom J, Siegbahn A, Reilly P, Themeles E, Oldgren J; RE-LY Investigators.
(A1 Refereed original research article in a scientific journal)
Decreased mortality risk due to first acute coronary syndrome in women with postmenopausal hormone therapy use (2016)
- Maturitas
Tuomikoski P, Salomaa V, Havulinna A, Airaksinen J, Ketonen M, Koukkunen H5, Ukkola O, Kesäniemi YA, Lyytinen H, Ylikorkala O, Mikkola TS
(A1 Refereed original research article in a scientific journal)
Design and Rationale of the RE-DUAL PCI Trial: A Prospective, Randomized, Phase 3b Study Comparing the Safety and Efficacy of Dual Antithrombotic Therapy With Dabigatran Etexilate Versus Warfarin Triple Therapy in Patients With Nonvalvular Atrial Fibrillation Who Have Undergone Percutaneous Coronary Intervention With Stenting (2016)
- Clinical Cardiology
Cannon CP, Gropper S, Bhatt DL, Ellis SG, Kimura T, Lip GY, Steg PG, Ten Berg JM, Manassie J, Kreuzer J, Blatchford J, Massaro JM, Brueckmann M, Ferreiros Ripoll E, Oldgren J, Hohnloser SH1; on behalf of the RE-DUAL PCISteering Committee and Investigators
(A1 Refereed original research article in a scientific journal)
Detecting atrial fibrillation via existing smartphones without any add-ons (2016)
- European Heart Journal Supplements
ESC Conference 2016 Tero Koivisto, Olli Lahdenoja, Tero Hurnanen, Timo Knuutila, Tuija Vasankari, Tuomas Kiviniemi, Antti Saraste, Juhani Airaksinen, Mikko Pänkäälä
(Other publication)
Detecting indications of acute myocardial infarction using smartphone only solution (2016) Tero Koivisto, Olli Lahdenoja, Tero Hurnanen, Mojtaba Jafari Tadi, Eero Lehtonen, Tuija Vasankari, Antti Saraste, Tuomas Kiviniemi, Juhani Airaksinen, Mikko Pänkäälä
(Other publication)